Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19
A Phase II Randomized Double-Blind Trial of Baricitinib or Placebo Combined With Antiviral Therapy in Patients With Moderate and Severe COVID-19
Sponsor: National Cancer Institute (NCI)
Terminated
The study was terminated after the release of results of ACTT-2 (NCT04401579).
Other terminated trials from National Cancer Institute (NCI)
A PHASE2 clinical study on Symptomatic COVID-19 Infection Laboratory-Confirmed, this trial is terminated or withdrawn. The trial is conducted by National Cancer Institute (NCI) and has accumulated 6 data snapshots since 2020. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jun 2021 — Jul 2024 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
Jun 2020 — Jul 2020 [monthly]
Recruiting PHASE2
First recorded
May 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- University of Southern California
For direct contact, visit the study record on ClinicalTrials.gov .